Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2002 Apr;3(4):627-33.

Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.

Author information

1
Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles 90033, USA. aaparici@usc.edu

Abstract

In recent years the importance of epigenetic changes in carcinogenesis has been unfolding. It is now clear that the fifth base of the genome, methylcytosine, plays a critical role in the control of gene expression during normal development and carcinogenesis. Efforts to decrease methylation in neoplasias as a therapeutic strategy have been productive in hematologic malignancies but disappointing in solid tumors. The following is a review of the clinical experience with the agents 5-azacytidine and 5-aza-2'-deoxycytidine in solid malignancies and a discussion of the difficulties encountered.

PMID:
12090735
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center